ESC Focus on Interventions & PC - 1

ESC Congress 2017

In Review

Interventions &
Peripheral Circulation
Dear Colleagues,
We are delighted to present this special issue of ESC Congress 2017 in Review, focused on peripheral arterial
diseases, which are increasingly prevalent in clinical practice and may be challenging to manage. The peerreviewed highlights in this issue are based on presentations at the European Society of Cardiology (ESC)
Congress 2017 held in Barcelona, Spain.
Within this issue, you will find a closer look at the newly published 2017 ESC Clinical Practice Guidelines
on the diagnosis and treatment of peripheral arterial diseases, which cover arterial disease in every location
except for the coronary and intracranial arteries as well as the aorta.
The Hot Line trials and late-breaking registry results presented in this issue include the COMPASS study
which demonstrated that the combination of rivaroxaban 2.5 mg BID plus aspirin was superior to rivaroxaban
5 mg BID or aspirin alone in reducing the primary outcome of major adverse cardiac events, as well as the
key outcome for PAD, major adverse limb events (defined as severe limb ischaemia leading to an intervention
and major amputation due to vascular insufficiency above the forefoot).
We hope that the articles and practical perspectives presented in ESC Congress 2017 in Review - Focus on
Interventions and Peripheral Circulation will provide you with new insights. Please be advised that in order to
access ESC Congress content (videos, slides, abstracts, and reports) all year long, visit us online at any time
at www.escardio.org/365.
We hope to see you in Munich for ESC Congress 2018. For more information, please visit www.escardio.org/ESC2018.

Professor Stephan Achenbach, FESC
ESC Congress Programme Committee Chair 2016-2018

Official Peer-Reviewed Highlights From ESC Congress 2017

1
http://www.escardio.org/365 http://www.escardio.org/ESC2018
Table of Contents for the Digital Edition of ESC Focus on Interventions & PC
